Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis

Kentaro Kikuchi, Willy Hsu, Naomi Hosoya, Yuki Moritoki, Yusuke Kajiyama, Toshihiro Kawai, Atsuko Takai, Eriko Hayami, Carlo Selmi, M. Eric Gershwin, Hiroshi Miyakawa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Aim: Ursodeoxycholic acid (UDCA) treatment reduces IgM serum levels in patients with primary biliary cirrhosis (PBC) without affecting serum antimitochondrial antibody (AMA) titers. We previously reported that PBC-associated hyper-IgM is secondary to a disease-specific hyperproduction following bacterial stimulation by B cells. Methods: We isolated peripheral blood mononuclear cells (PBMC) from patients with PBC and controls and evaluated whether bacterial CpG challenge in the presence of UDCA at concentrations consistent with those achieved in treated patients led to changes in total IgM, IgG-AMA, and IgM-AMA production. Further, p65 phosphorylation and CD38 cell expression were analyzed as measures of activation of the NF-kB signaling pathway and B cell subsets, respectively. Results: UDCA significantly reduced CpG-induced total IgM and IgM-AMA production, but had no impact on IgG-AMA production. UDCA also significantly reduced the activation ofnaïve and IgM memory, but not IgG memory, B cells, as represented by CD38 expression levels. Further, p65 phosphorylation was significantly reduced in the presence of UDCA. Conclusion: UDCA reduces total and IgM-AMA production in PBMC from patients with PBC by downregulating B cell activation and NF-kB signaling. These data ultimately suggest novel mechanisms of action for UDCA in chronic autoimmune cholestasis.

Original languageEnglish (US)
Pages (from-to)448-454
Number of pages7
JournalHepatology Research
Volume39
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Immunoglobulin M
Antibody Formation
B-Lymphocytes
NF-kappa B
Immunoglobulin G
Blood Cells
Phosphorylation
B-Lymphocyte Subsets
Antibodies
Cholestasis
Serum
Down-Regulation

Keywords

  • Autoantibody
  • Autoimmune cholangitis
  • Bile acids
  • Innate immunity

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Kikuchi, K., Hsu, W., Hosoya, N., Moritoki, Y., Kajiyama, Y., Kawai, T., ... Miyakawa, H. (2009). Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis. Hepatology Research, 39(5), 448-454. https://doi.org/10.1111/j.1872-034X.2008.00474.x

Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis. / Kikuchi, Kentaro; Hsu, Willy; Hosoya, Naomi; Moritoki, Yuki; Kajiyama, Yusuke; Kawai, Toshihiro; Takai, Atsuko; Hayami, Eriko; Selmi, Carlo; Gershwin, M. Eric; Miyakawa, Hiroshi.

In: Hepatology Research, Vol. 39, No. 5, 2009, p. 448-454.

Research output: Contribution to journalArticle

Kikuchi, K, Hsu, W, Hosoya, N, Moritoki, Y, Kajiyama, Y, Kawai, T, Takai, A, Hayami, E, Selmi, C, Gershwin, ME & Miyakawa, H 2009, 'Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis', Hepatology Research, vol. 39, no. 5, pp. 448-454. https://doi.org/10.1111/j.1872-034X.2008.00474.x
Kikuchi, Kentaro ; Hsu, Willy ; Hosoya, Naomi ; Moritoki, Yuki ; Kajiyama, Yusuke ; Kawai, Toshihiro ; Takai, Atsuko ; Hayami, Eriko ; Selmi, Carlo ; Gershwin, M. Eric ; Miyakawa, Hiroshi. / Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis. In: Hepatology Research. 2009 ; Vol. 39, No. 5. pp. 448-454.
@article{edf96d2564084d6a9e1af59c4cfe5ec1,
title = "Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis",
abstract = "Aim: Ursodeoxycholic acid (UDCA) treatment reduces IgM serum levels in patients with primary biliary cirrhosis (PBC) without affecting serum antimitochondrial antibody (AMA) titers. We previously reported that PBC-associated hyper-IgM is secondary to a disease-specific hyperproduction following bacterial stimulation by B cells. Methods: We isolated peripheral blood mononuclear cells (PBMC) from patients with PBC and controls and evaluated whether bacterial CpG challenge in the presence of UDCA at concentrations consistent with those achieved in treated patients led to changes in total IgM, IgG-AMA, and IgM-AMA production. Further, p65 phosphorylation and CD38 cell expression were analyzed as measures of activation of the NF-kB signaling pathway and B cell subsets, respectively. Results: UDCA significantly reduced CpG-induced total IgM and IgM-AMA production, but had no impact on IgG-AMA production. UDCA also significantly reduced the activation ofna{\"i}ve and IgM memory, but not IgG memory, B cells, as represented by CD38 expression levels. Further, p65 phosphorylation was significantly reduced in the presence of UDCA. Conclusion: UDCA reduces total and IgM-AMA production in PBMC from patients with PBC by downregulating B cell activation and NF-kB signaling. These data ultimately suggest novel mechanisms of action for UDCA in chronic autoimmune cholestasis.",
keywords = "Autoantibody, Autoimmune cholangitis, Bile acids, Innate immunity",
author = "Kentaro Kikuchi and Willy Hsu and Naomi Hosoya and Yuki Moritoki and Yusuke Kajiyama and Toshihiro Kawai and Atsuko Takai and Eriko Hayami and Carlo Selmi and Gershwin, {M. Eric} and Hiroshi Miyakawa",
year = "2009",
doi = "10.1111/j.1872-034X.2008.00474.x",
language = "English (US)",
volume = "39",
pages = "448--454",
journal = "International Hepatology Communications",
issn = "0928-4346",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis

AU - Kikuchi, Kentaro

AU - Hsu, Willy

AU - Hosoya, Naomi

AU - Moritoki, Yuki

AU - Kajiyama, Yusuke

AU - Kawai, Toshihiro

AU - Takai, Atsuko

AU - Hayami, Eriko

AU - Selmi, Carlo

AU - Gershwin, M. Eric

AU - Miyakawa, Hiroshi

PY - 2009

Y1 - 2009

N2 - Aim: Ursodeoxycholic acid (UDCA) treatment reduces IgM serum levels in patients with primary biliary cirrhosis (PBC) without affecting serum antimitochondrial antibody (AMA) titers. We previously reported that PBC-associated hyper-IgM is secondary to a disease-specific hyperproduction following bacterial stimulation by B cells. Methods: We isolated peripheral blood mononuclear cells (PBMC) from patients with PBC and controls and evaluated whether bacterial CpG challenge in the presence of UDCA at concentrations consistent with those achieved in treated patients led to changes in total IgM, IgG-AMA, and IgM-AMA production. Further, p65 phosphorylation and CD38 cell expression were analyzed as measures of activation of the NF-kB signaling pathway and B cell subsets, respectively. Results: UDCA significantly reduced CpG-induced total IgM and IgM-AMA production, but had no impact on IgG-AMA production. UDCA also significantly reduced the activation ofnaïve and IgM memory, but not IgG memory, B cells, as represented by CD38 expression levels. Further, p65 phosphorylation was significantly reduced in the presence of UDCA. Conclusion: UDCA reduces total and IgM-AMA production in PBMC from patients with PBC by downregulating B cell activation and NF-kB signaling. These data ultimately suggest novel mechanisms of action for UDCA in chronic autoimmune cholestasis.

AB - Aim: Ursodeoxycholic acid (UDCA) treatment reduces IgM serum levels in patients with primary biliary cirrhosis (PBC) without affecting serum antimitochondrial antibody (AMA) titers. We previously reported that PBC-associated hyper-IgM is secondary to a disease-specific hyperproduction following bacterial stimulation by B cells. Methods: We isolated peripheral blood mononuclear cells (PBMC) from patients with PBC and controls and evaluated whether bacterial CpG challenge in the presence of UDCA at concentrations consistent with those achieved in treated patients led to changes in total IgM, IgG-AMA, and IgM-AMA production. Further, p65 phosphorylation and CD38 cell expression were analyzed as measures of activation of the NF-kB signaling pathway and B cell subsets, respectively. Results: UDCA significantly reduced CpG-induced total IgM and IgM-AMA production, but had no impact on IgG-AMA production. UDCA also significantly reduced the activation ofnaïve and IgM memory, but not IgG memory, B cells, as represented by CD38 expression levels. Further, p65 phosphorylation was significantly reduced in the presence of UDCA. Conclusion: UDCA reduces total and IgM-AMA production in PBMC from patients with PBC by downregulating B cell activation and NF-kB signaling. These data ultimately suggest novel mechanisms of action for UDCA in chronic autoimmune cholestasis.

KW - Autoantibody

KW - Autoimmune cholangitis

KW - Bile acids

KW - Innate immunity

UR - http://www.scopus.com/inward/record.url?scp=65449131223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449131223&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2008.00474.x

DO - 10.1111/j.1872-034X.2008.00474.x

M3 - Article

C2 - 19207576

AN - SCOPUS:65449131223

VL - 39

SP - 448

EP - 454

JO - International Hepatology Communications

JF - International Hepatology Communications

SN - 0928-4346

IS - 5

ER -